Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Redx Pharma Plc RNS Release

Statement re. Suspension

RNS Number : 1689G
Redx Pharma plc
24 May 2017
 

24 May 2017

REDX PHARMA PLC

("Redx" or "the Company")

 

LIVERPOOL CITY COUNCIL CALL IN LOAN

Suspension of Trading

Appointment of Administrators

 

Redx, the drug discovery and development company, announces that the Company has requested a suspension of its shares from trading on the AIM market of the London Stock Exchange with immediate effect having been informed that administrators have been appointed to the Company.

 

By way of background, the Company received a formal demand for repayment of a loan that was made to a subsidiary of the Company, RedX Oncology Limited, by Liverpool City Council ("LCC") in June 2012 (the "Loan").  The terms of the Loan were amended in March 2015 such that the maturity date of the Loan was extended to 31 March 2017 ("Maturity Date").  The Loan amount is £2 million, together with interest at 12 per cent. per annum, which has been accrued and also fell due for repayment on the Maturity Date.

 

The Company has been in discussions with LCC regarding the repayment and/or restructuring of the terms of the Loan (involving an initial payment and ongoing monthly payments), in order to reach an amicable settlement, but these discussions, despite considerable effort on the part of the board, have not been successfully concluded.

 

The Company has been actively seeking to negotiate directly with LCC and also to secure alternative sources of finance in order to facilitate repayment of the Loan at the earliest practicable opportunity.  The Company offered LCC an immediate payment of £1 million in return for a short grace period in which to repay the outstanding amount. This offer was rejected.

 

The Company understands that FRP Advisory LLP was appointed administrators to the Company and RedX Oncology Limited earlier this afternoon.

 

Iain Ross, recently appointed Chairman of the Company commented:

 

"The timing of this action by LCC and its advisers FRP is extremely unfortunate and quite baffling considering our efforts to have face to face discussions, including earlier today, the immediate offer of a payment plan and our latest proposal to make an immediate £1million payment in return for a short grace period. The Board and its advisers felt consistently confident that we could have found the appropriate solution within a short period and can't quite fathom why a creditor with whom we have had a good relationship for over 5 years is taking such an aggressive stance when they know, and have been provided with the evidence, that the Company is making excellent progress on all fronts.

 

The Company, which now comprises 84 employees, has two incredibly important state of the art cancer programs, which will shortly commence clinical development in seriously ill patients and both these assets are attracting significant partnering interest from a number of large pharmaceutical companies. Despite this and our assurances to resolve the matter quickly, LCC has refused to meet with me or to have any direct discussion."

 

Further announcements will be made in due course.

 

 

For further information, please contact:

 

Redx Pharma Plc

 

Neil Murray, Chief Executive Officer

T: +44 1625 469 900 

Karl Hård, Head of Investor Relations &

Corporate Communications

T: +44 7491 651 406

 

Cantor Fitzgerald Europe (Nomad & Broker)

 

T: +44 20 7894 7000

Phil Davies/ Michael Reynolds

 

 

 

WG Partners LLP (Joint Broker)

T: +44 20 3705 9330

Claes Spång/ Chris Lee/ David Wilson

 

 

Consilium Strategic Communications

 T: +44 20 3709 5700                                       

Amber Fennell/ Matthew Neal/ Melissa Gardiner          

 

 

 

 

About Redx Pharma Plc

Company website: redxpharma.com

 

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
SRSEAXSLADDXEFF



Redx Pharma Plc Timeline

CN Research
April 06 2017

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use